Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 2/20 | 0.48 |
| ▸ | NPY4R | P50391 | 11/20 | 0.38 |
| ▸ | NPY1R | P25929 | 6/20 | 0.38 |
| ▸ | NPY2R | P49146 | 4/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.36 |
| ▸ | RRM1 | P23921 | 1/20 | 0.36 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.34 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.34 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL607060 | 0.82 | NOS1 (0.46) | NOS1DPP7MEN1NOS3KMT2A | |
| SCHEMBL5983469 | 0.82 | NOS1 (0.46) | NOS1DPP7MEN1NOS3KMT2A | |
| Nitroarginine SCHEMBL881062 | 0.77 | NOS1 (0.48) | NOS1NOS3 | |
| Nitroarginine SCHEMBL28365071 | 0.77 | NOS1 (0.48) | NOS1NOS3 | |
| Nitroarginine SCHEMBL345312 | 0.77 | NOS1 (0.48) | NOS1NOS3 | |
| SCHEMBL608402 | 0.76 | NOS1 (0.49) | NOS1NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL24121685 | 0.76 | NPY4R (0.55) | NPY4RNPY1RNPY2RNPY5RDPP7 | |
| SCHEMBL29947113 | 0.76 | NPY4R (0.55) | NPY4RNPY1RNPY2RNPY5RDPP7 | |
| SCHEMBL31467756 | 0.75 | NPY4R (0.53) | NPY4RNPY1RNPY2RNPY5RDPP7 | |
| SCHEMBL10190207 | 0.74 | DPP7 (0.44) | NOS1NPY4RNPY1RNPY2RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176907-A1 | NOS Inhibitors For Treatment Of Motor Deficit Disorders | NORTHWESTERN UNIVERSITY (US) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176907-A1 | NOS Inhibitors For Treatment Of Motor Deficit Disorders | NOS1, NOS3, SMN1; SMN2 | NOS1 1/4885NPY4R 2337/4885NPY1R 2030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.